Millendo Therapeutics Inc (MLND) Stock Price, Forecast & Analysis
USA - NASDAQ:MLND -
MLND Key Statistics, Chart & Performance
The current stock price of MLND is 1.06 null. In the past month the price decreased by -7.02%. In the past year, price decreased by -41.44%.
MLND Latest News, Press Relases and Analysis
MLND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About MLND
Company Profile
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Company Info
Millendo Therapeutics Inc
Ann Arbor MICHIGAN 48104 US
CEO: Louis Arcudi
Phone: 17348459000.0
Millendo Therapeutics Inc / MLND FAQ
What does Millendo Therapeutics Inc do?
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
What is the stock price of Millendo Therapeutics Inc today?
The current stock price of MLND is 1.06 null. The price decreased by -5.36% in the last trading session.
Does Millendo Therapeutics Inc pay dividends?
MLND does not pay a dividend.
How is the ChartMill rating for Millendo Therapeutics Inc?
MLND has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is MLND stock listed?
MLND stock is listed on the Nasdaq exchange.
Can you provide the market cap for Millendo Therapeutics Inc?
Millendo Therapeutics Inc (MLND) has a market capitalization of 20.19M null. This makes MLND a Nano Cap stock.
MLND Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLND. When comparing the yearly performance of all stocks, MLND is a bad performer in the overall market: 98.82% of all stocks are doing better.
MLND Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLND. Both the profitability and financial health of MLND have multiple concerns.
MLND Financial Highlights
Over the last trailing twelve months MLND reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 44.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.44% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
MLND Forecast & Estimates
0 analysts have analysed MLND and the average price target is 2.04 null. This implies a price increase of 92.45% is expected in the next year compared to the current price of 1.06.